BONESUPPORT’s antibiotic-eluting bone graft CERAMENT G (Gentamicin) has been used surgically for the first time in patients in the U.S. The patients treated had bone infection caused by fractures induced by trauma.
BONESUPPORT received authorization for CERAMENT G in the management of osteomyelitis from FDA earlier this year. The extensive clinical documentation on which the market approval is based, shows that CERAMENT G reduces the risk of recurrent bone infection to 4.3% to 5.5% versus 13.3% for the current U.S. standard of care, which is PMMA-beads. CERAMENT G is reported to be the first and only FDA-authorized combination antibiotic eluting bone graft.
BONESUPPORT’s CERAMENT G is an implantable device/drug combination bone void filler that provides a pathway for a one-stage approach to the management of bone infection with its dual mode of action that delivers bone remodeling with reliable and safe local elution of a broad-spectrum antibiotic.
Source: BONESUPPORT
BONESUPPORT's antibiotic-eluting bone graft CERAMENT G (Gentamicin) has been used surgically for the first time in patients in the U.S. The patients treated had bone infection caused by fractures induced by trauma.
BONESUPPORT received authorization for CERAMENT G in the management of osteomyelitis from FDA earlier this year. The extensive...
BONESUPPORT’s antibiotic-eluting bone graft CERAMENT G (Gentamicin) has been used surgically for the first time in patients in the U.S. The patients treated had bone infection caused by fractures induced by trauma.
BONESUPPORT received authorization for CERAMENT G in the management of osteomyelitis from FDA earlier this year. The extensive clinical documentation on which the market approval is based, shows that CERAMENT G reduces the risk of recurrent bone infection to 4.3% to 5.5% versus 13.3% for the current U.S. standard of care, which is PMMA-beads. CERAMENT G is reported to be the first and only FDA-authorized combination antibiotic eluting bone graft.
BONESUPPORT’s CERAMENT G is an implantable device/drug combination bone void filler that provides a pathway for a one-stage approach to the management of bone infection with its dual mode of action that delivers bone remodeling with reliable and safe local elution of a broad-spectrum antibiotic.
Source: BONESUPPORT
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.